Timothy Gilbert, MD
Endocrinology, Diabetes & Metabolism · Baton Rouge, LANPI 1467568600
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $818,282 of the $984,503 with a category attached, or 83.1%. 57 manufacturers reported payments, led by AstraZeneca at 34.5% of the total. Reporting peaked in 2019 at $251,400 and has fallen 71.9% since, to $70,660 in 2025. Among endocrinology, diabetes & metabolism clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,554 payments — averaging $633.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$339K
- Novo Nordisk$270K
- Dexcom, Inc.$242K
- Sanofi-aventis U.S. LLC$88K
- Insulet Corporation$13K
- Boehringer Ingelheim$13K
- plus $20K from 51 others
What the payments were for
- Consulting fees$14,3601%
- Speaking & faculty fees$818,28283%
- Travel & lodging$118,54812%
- Food & beverage$33,1813%
- Education$730%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$335,890
- Wegovy$123,434
- DEXCOM G7 GSS (161)$94,427
- RYBELSUS$74,639
- DEXCOM G6 TRANSMITTER$67,778
- SOLIQUA 100/33$62,976
- Ozempic$60,288
- DEXCOM CGM$42,593
- TOUJEO$39,006
- DEXCOM G6 CGM SYSTEM$34,153
- JARDIANCE$19,923
- Omnipod$12,695
- DEXCOM STELO GLUCOSE BIOSENSOR$7,369
- Saxenda$6,574
- Eversense$3,500
- InPen$504
- INPEN SMART INSULIN DELIVERY SYSTEM$499
- MINIMED 780G$349
- BYDUREON$182
- TEPEZZA$136
How this compares
$984,503 in reported general payments places this provider in the 95th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 243 | $285,761 |
| MounjaroTirzepatide | 165 | $190,960 |
| FarxigaDapagliflozin Propanediol | 87 | $88,443 |
| JardianceEmpagliflozin | 66 | $57,202 |
| Xigduo XrDapaglifloz Propaned/Metformin | 69 | $54,931 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $50,433 |
| JanuviaSitagliptin Phosphate | 41 | $36,446 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 33 | $33,508 |
| TrulicityDulaglutide | 16 | $31,930 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 29 | $28,258 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $26,368 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 22 | $17,737 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 20 | $16,083 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $15,448 |
| SynthroidLevothyroxine Sodium | 168 | $15,214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $269,722 | $290,966262 claims |
| Lilly USA, LLCMounjaro, Trulicity | $8,576 | $222,890181 claims |
| AstraZenecaFarxiga | $339,366 | $88,44387 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $12,793 | $73,28586 claims |
| MerckJanuvia | $295 | $36,44641 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $87,787 | $28,25829 claims |
| AbbVieSynthroid | $340 | $15,214168 claims |
| Antares Pharma, Inc.Xyosted | $244 | $10,35817 claims |
| Astellas Pharma US IncVeozah | $91 | $9,68818 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $126 | $2,883344 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Baton Rouge
- Frank GreenwayBaton Rouge$42K
- Ivan GamboaBaton Rouge$25K
- Jonathan WeldenBaton Rouge$24K
- Brittani BreauxBaton Rouge$18K
- Lourdes RodriguezBaton Rouge$17K
- Robin KilpatrickBaton Rouge$12K
- Lauren CutroneBaton Rouge$11K
- Jolene JohnsonBaton Rouge$10K
- Shatha MuradBaton Rouge$2K
- Roopitha KavalBaton Rouge$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.